GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (NAS:MEDP) » Definitions » EBIT

Medpace Holdings (Medpace Holdings) EBIT : $354 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings EBIT?

Medpace Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $104 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $354 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medpace Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was 21.58%. Medpace Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 159.25%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medpace Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 2.92%.


Medpace Holdings EBIT Historical Data

The historical data trend for Medpace Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings EBIT Chart

Medpace Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 127.26 167.04 198.62 278.70 336.83

Medpace Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.20 77.11 83.31 89.52 104.07

Competitive Comparison of Medpace Holdings's EBIT

For the Diagnostics & Research subindustry, Medpace Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's EV-to-EBIT falls into.



Medpace Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $354 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medpace Holdings  (NAS:MEDP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medpace Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=416.276 * ( 1 - 9.04% )/( (1739.123 + 1770.026)/ 2 )
=378.6446496/1754.5745
=21.58 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1656.828 - 249.008 - ( 245.449 - max(0, 925.131 - 593.828+245.449))
=1739.123

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1795.789 - 237.506 - ( 407.01 - max(0, 956.645 - 744.902+407.01))
=1770.026

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Medpace Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=416.276/( ( (265.39 + max(-599.22, 0)) + (257.403 + max(-627.234, 0)) )/ 2 )
=416.276/( ( 265.39 + 257.403 )/ 2 )
=416.276/261.3965
=159.25 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(275.932 + 0 + 49.979) - (249.008 + 559.86 + 116.263)
=-599.22

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(270.685 + 0 + 58.726) - (237.506 + 616.697 + 102.442)
=-627.234

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medpace Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=354.003/12129.012
=2.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medpace Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medpace Holdings (Medpace Holdings) Business Description

Traded in Other Exchanges
Address
5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Executives
Susan E Burwig officer: Exec. VP, Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
August J. Troendle director, 10 percent owner, officer: CEO 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Investors, Llc 10 percent owner 4620 WESLEY AVENUE, CINCINNATI OH 45212
Robert O. Kraft director ONE CVS DRIVE, WOONSOCKET RI 02895
Kevin M. Brady officer: CFO & Treasurer MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Stephen P Ewald officer: General Counsel & Corp. Secy. C/O MEDPACE HOLDINGS,INC., 5375 MEDPACE WAY, CINTINNATI OH 45227
Femida H. Gwadry-sridhar director 5375 MEDPACE WAY, CINCINNATI OH 45227
Ashley M. Keating director 5375 MEDPACE WAY, CINCINNATI OH 45227
Davenport Fred B Jr director
Brian T Carley director C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Mccarthy Cornelius P. Iii director 5375 MEDPACE WAY, CINCINNATI OH 45227
Jesse J Geiger officer: CFO & COO, Lab Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Tom C King director 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Limited Partnership 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT, CHANNEL ISLANDS Y7 GY1 3PP
Cinven Capital Management (v) General Partner Ltd 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT Y7 GY1 3PP